Emmaus Life Sciences, Inc. Quarterly report [Sections 13 or 15(d)]

Selected Financial Statement - Liabilities (Tables)

3 Months Ended

Mar. 31, 2025

Accounts payable and accrued expenses consisted of the following at March 31, 2025 and December 31, 2024 (in thousands):


	March 31, 2025		December 31, 2024
Accounts payable:
Clinical and regulatory expenses	$	514	$	452
Professional fees		608		904
Selling expenses		1,516		1,553
Manufacturing costs		695		706
Non-employee director compensation		954		966
Other vendors		520		594
Total accounts payable		4,807		5,175
Accrued interest payable, related parties		1,274		1,145
Accrued interest payable		3,492		2,874
Accrued expenses:
Payroll expenses		466		323
Government rebates and other rebates		7,809		7,229
Due to customers		—		15
Other accrued expenses		465		165
Total accrued expenses		8,740		7,732
Total accounts payable and accrued expenses	$	18,313		16,926

Other current liabilities consisted of the following at March 31, 2025 and December 31, 2024 (in thousands):


	March 31, 2025		December 31, 2024
Trade discount	$	5,100	$	5,000
Unearned revenue (a)		10,000		10,000
Other current liabilities		1,303		1,557
Total other current liabilities	$	16,403	$	16,557

(a) Refer to Note 3 for information regarding to due to Telcon.

Other long-term liabilities consisted of the following at March 31, 2025 and December 31, 2024 (in thousands):



	March 31, 2025		December 31, 2024
Trade discount	$	13,323	$	13,421
Other long-term liabilities		46		44
Total other long-term liabilities	$	13,369	$	13,465